China Biologic Products Hosts its First Forum for Strategy and Development
TAIAN CITY, China, July 16 /PRNewswire-Asia-FirstCall/ -- China Biologic
Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic" or the "Company"),
one of the leading plasma-based pharmaceutical companies in the People's
Republic of China ("PRC"), today announced that the Company hosted a ...
PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review
ANNAPOLIS, Md., July 9 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Company's propos...
Arpida to Discuss Strategy With Shareholders
REINACH, Switzerland, May 7 /PRNewswire-FirstCall/ -- Arpida Ltd. (SIX:
ARPN) will today discuss potential strategic scenarios with its shareholders
during the Annual General Meeting (AGM) which starts at 10am CET in Reinach,
After the negative FDA opinion regarding intrave...
Healthplace America Engages Robert A. Yungk to Provide Services as Chief Strategy Officer
Mr. Yungk to Direct Strategic Development of the Company's National Network of Medical Provider Best Practice Leaders
LISLE, Ill., April 7 /PRNewswire/ -- Healthplace America, the country's first and only Surgery Benefit Management(TM) solution company, is engaging the services of Robert A. Y...
Independent Study Corroborates Prana's Strategy to Treat Alzheimer's Disease Patients.
- Journal of Neuroscience paper describes role of Zinc in developing Alzheimer's -
MELBOURNE, Australia, April 1 /PRNewswire-FirstCall/ -- Prana Biotechnology (ASX:PBT; Nasdaq: PRAN ) today announced that an independent study conducted by researchers at the University of California, Irvine...
Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates
SAN DIEGO, March 25 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) today announced clinical data that supports the advancement of the Aethlon Hemopurifier(R) as an adjunct therapy to increase Hepatitis-C (HCV) cure rates. The Hemopurifier(R) is a first-in-class medical ...
Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
CHENGDU, China, March 17 /PRNewswire-Asia-FirstCall/ -- Tianyin
Pharmaceutical, Co., Inc., (NYSE Alternext: TPI), a manufacturer and supplier
of modernized traditional Chinese medicine ("TCM") based in Chengdu, China,
today announced it has adopted a new sales strategy
Perceptive Informatics Receives Frost & Sullivan Product Line Strategy Award
BOSTON, Feb. 24 /PRNewswire-FirstCall/ -- Perceptive Informatics, the industry's leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL ), today announced that it has received the Frost & Sullivan Product Line Strategy
Award. Frost & Sul...
CFSO Calls for Roundtable to Develop National Strategy for Advancing Forensic Sciences in the United States
DENVER, Feb. 17 /PRNewswire-USNewswire/ -- AAFS Convention -- With
tomorrow's release of the Forensics Study by the National Academy of Sciences,
The Consortium of Forensic Science Organizations (CFSO) has announced that:
-- Peter Marone, CFSO chairman, will be available to the media f...
DuPont Unveils New Strategy to Expand its Seed Business
Pioneer Hi-Bred Partners with Seed Companies to Introduce New Products, Brands.
Chicago, IL (Vocus) December 11, 2008 —- DuPont business Pioneer Hi-Bred today unveiled a new business strategy
to bring its seed genetics to more acres around the world through a ne...
Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance
NEW YORK, Dec. 11 /PRNewswire-FirstCall/ --
-- Innovation and Patient-Centered Approach Expected to Drive Future
-- Lilly Climbs into Top 10 Pharmaceutical Companies in Worldwide Sales
and Is Fastest Growing in U.S.
-- FIPNet Strategy
Expands Global Reach and...
Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
CHENGDU, China, Dec. 2 /PRNewswire-Asia-FirstCall/ -- Tianyin
Pharmaceutical, Co., Inc., (NYSE EuroNext: TPI), a manufacturer and supplier
of modernized traditional Chinese medicine ("TCM") based in Chengdu, China,
today announced the implementation of a new sales and marketing strategy
White Paper Examines New 'Thin LIMS' IT Implementation Strategy for cGMP Quality Informatics
HOPKINTON, Mass., Oct. 20 /PRNewswire/ -- The implementation of a
compliant Laboratory Information Management System (LIMS) for the QC/QA
laboratory environment is often victimized by "scope creep," with costs
rising 2 to 5 times above originals estimates and forcing the continued
funding of a...
Solos Endoscopy, Inc. Implements Strategy to Capitalize on $30 Billion Minimally Invasive Surgical Product Market
BOSTON, Sept. 30 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink
Sheets: SNDY) is pleased to announce that the Company intends to expand
their current industry to include and capitalize on the $30 billion
minimally invasive instrumentation market by implementing a business
strategy. The ...
WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
SHANGHAI, China, Sept. 29 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:
WX), a leading pharmaceutical, biotechnology and medical device research
and development outsourcing company with operations in China and the United
States, announced today that it will no longer pursue a 50-50 joint ventu...
Covance Decides to Pursue Its Original Preclinical Strategy in China
PRINCETON, N.J., Sept. 29 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE:
CVD) announced today that it will no longer pursue a 50-50 joint venture
with WuXi Pharmatech to provide preclinical contract research services in
"We expect China will become an attractive region for outsourced d...
Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
PARIS, September 10 /PRNewswire-FirstCall/ --
- Abstracts 185 and 1112
Sanofi-aventis, a world leader in diabetes care, announced results from
two randomized clinical studies presented at the European Association for
the Study of Diabetes (EASD) 44th Annual Meeting demonstrating that the
Anesiva Announces Conference Call and Webcast to Discuss Updates to Corporate Strategy and Milestones
SOUTH SAN FRANCISCO, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Anesiva,
Inc. (Nasdaq: ANSV ) announced that it will hold a conference call and
webcast on Wednesday, September 3, 2008 at 11:30 am Eastern time (8:30 am
Pacific time). During the call, Anesiva management will update its
Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development
Former Organon Exec Will Help Drive Company's Commercialization of
CEDAR KNOLLS, N.J., Aug. 19 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS ) has announced that Nicholas J. Hart has
joined the company as Vice President of Strategy
Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
VEDBAEK, Denmark, July 24 /PRNewswire-FirstCall/ -- Frost & Sullivan
has announced the selection of Exiqon as the recipient of its 2008 Growth
Strategy Leadership Award in the molecular diagnostic market. This award
follows Frost & Sullivan's most recent analysis of the molecular diagnostic
GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO
LONDON, July 23 /PRNewswire-FirstCall/ -- In a video interview, new CEO
Andrew Witty comments on GSK's second quarter results while also updating
the market on his strategic vision for the business.
The new strategic priorities for GlaxoSmithKline are:
- Grow a diversified global busin...
CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing
BOTHELL, Wash., July 9 /PRNewswire-FirstCall/ -- CellCyte Genetics
Corporation (CellCyte) (OTC Bulletin Board: CCYG) has engaged InCap Group,
Inc. (InCap) to provide strategic investment and financial advice and
services. CellCyte seeks to build shareholder value by monetizing its two
Mega-Brand Success: Effective Market Strategy and Tactics
CHAPEL HILL, N.C., June 10 /PRNewswire/ -- Pharmaceutical companies can
literally add -- or subtract -- billions of dollars in the lifetime cash
flows of potential mega-brands. Research and development groups no longer
singularly drive the value of a new product. Sales and Marketing teams also...
American Oriental Bioengineering Appoints Anindya Chatterjee to Chief Strategy Officer
- Anindya Chatterjee Brings Over Thirteen Years of Capital Markets Experience to AOBO -
- New Role Emphasizes Strategic Growth Plan and Capital Markets Interaction -
NEW YORK, June 9 /PRNewswire-FirstCall/ -- American Oriental
Sosei Announces Outcome of Strategy Review
TOKYO, May 14 /PRNewswire-FirstCall/ -- Sosei Group Corporation
("Sosei"; TSE Mothers Index: 4565), a biopharmaceutical company, today
announces the outcome of its strategy
In view of the current market conditions, the difficulty in raising
finance at the current low share price, and...
Chindex International Announces Shelf Registration, Related Strategy and Guidance
BETHESDA, Md., May 13 /Xinhua-PRNewswire/ -- Chindex International,
Inc. (Nasdaq: CHDX ), a leading independent American provider of Western
healthcare services and products in the People's Republic of China,
announced that it has filed a shelf registration statement with the
Securities and E...
Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing
Confirms commitment to accelerating market penetration and revenue growth
SCOTTSDALE, Ariz., May 1 /PRNewswire/ -- Regenesis Biomedical, Inc., a
medical technology company that markets the Provant(R) Wound Therapy
System, announced today that Scott Robey joined the company as Vice
President of ...
Scientists develop strategy to rapidly describe outbreak strains with next-generation DNA sequencing
Friday, April 11, 2008 In the event of an outbreak or a bioterrorist attack, rapid identification of the genetic changes responsible for virulence or drug resistance is essential to mounting an effective response. Standard DNA sequencing and analysis of a pathogen genome is time-intensive and li...
Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
WASHINGTON DC, April 2 /PRNewswire-FirstCall/ -- Bavarian Nordic, the
Danish-based biopharmaceutical company, recently published its 2007 Annual
Report. Below is an extract of the most significant matters in the report
as well as events after the balance sheet date.
Bavarian Nordic's revenue...
Cardiac Science Unveils Major Brand Change; Strategy to Lift Brand Awareness
BOTHELL, Wash., March 6 /PRNewswire-FirstCall/ -- Cardiac Science
Corporation (Nasdaq: CSCX ), a global leader in advanced cardiac diagnosis,
resuscitation, rehabilitation, and informatics products, announced today
that it aligned the power of its leading product brands (Burdick(R),
Emisphere to Host Business Strategy Conference Call on February 7
- CEO Michael V. Novinski to Discuss Plans for Company in 2008 and Beyond -
CEDAR KNOLLS, N.J., Jan. 31 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS ), announced today that it will host a
teleconference on Thursday, February 7, at 10:00 AM EST. President and
Co-Inventor of Amgen's Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals' First-in-Class Oxygen Enhancing Therapeutics
CHARLOTTESVILLE, Va., Dec. 21 /PRNewswire/ -- Diffusion Pharmaceuticals
LLC, a clinical stage drug-development company commercializing
first-in-class drugs utilizing a novel mechanism of action that enhances
oxygen diffusion, today announced that one of its key advisors, Mr. Thomas
Byrne, was ...
Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community
* Expects Productivity Transformation Initiative to Generate Pre-Tax Cost
Savings and Avoidance of Approximately $1.5 Billion by 2010 and Incur
Associated Pre-Tax Costs of $900 Million to $1.1 Billion - Reducing Total Headcount by 10%
* Announces 11% Increase in ...
Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research
PHILADELPHIA, Nov. 29 /PRNewswire/ -- As part of an ongoing commitment
to help clients reduce product development times and maximize commercial
impact of their products, Premier Research Group plc (AIM: PRG) announced
today the consolidation of its industry-leading expertise in its core
Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
SAN DIEGO, May 11 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity, today announced that Jay Hagan has joined the organization as Senior Vice President of Corporate Development and Strategy.
Immunotech Laboratories Announces South American Strategy
GLENDALE, Calif., April 3 /PRNewswire-FirstCall/ -- Immunotech Laboratories (Pink Sheets: IMMB) is happy to announce preliminary discussions in setting up a potential venture for South America, headquartered in Mexico.
According to Ara Ghanime, Chairman of Immunotech Laboratories, the poten...
Obio Pharmaceutical Announces Product Growth Strategy
HONG KONG, Feb. 18 /PRNewswire-Asia/ -- Obio Pharmaceutical Holdings Ltd
("Obio"/ "the Company") announced its business growth ticket to the
international pharmaceutical arena. With a strong product pipeline in drug
development, backed up by strong international investors including Yangtze
Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
Claims extend and strengthen Odyssey Thera's coverage to include GPCR directed screening and drug profiling.
SAN RAMON, Calif., Feb. 12 /PRNewswire/ -- Odyssey Thera, Inc. announced today that it has been granted a United States patent entitled "Fragment Complementation Assays for G-Protein-C...
Panel blasts federal nanotech risk research strategy
Washington, DC A National Research Council (NRC) committee today issued a highly critical report describing serious shortfalls in the Bush administration's strategy
to better understand the environment, health and safety (EHS) risks of nanotechnology and to effectively manage those potential risk...
PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
BOSTON, Oct. 29 /PRNewswire-FirstCall/ -- PAREXEL International
Corporation (Nasdaq: PRXL ), a leading global biopharmaceutical services
provider, in partnership with Glenmark Pharmaceuticals Ltd, today announced
that it has been recognized by the Good Clinical Practice Journal (GCPj) as